Page 188 - EJMO-9-2

Eurasian Journal of
Medicine and Oncology PD-1/L1 inhibitors in advanced CC: Multicenter retro

an immune checkpoint inhibitor with lenvatinib. Anticancer 43. Walsh RJ, Tan DSP. The role of immunotherapy in the
Res. 2024;44(2):503-510. treatment of advanced cervical cancer: Current status and
future perspectives. J Clin Med. 2021;10(19):4523.
doi: 10.21873/anticanres.16838
doi: 10.3390/jcm10194523
41. Wu Z, Tao H, Zhang S, et al. Efficacy and safety of anti-PD-
1-based therapy in combination with PARP inhibitors for 44. FDA approves pembrolizumab with chemoradiotherapy
patients with advanced solid tumors in a real-world setting. for FIGO 2014 Stage III-IVA cervical cancer 2024-
Cancer Immunol Immunother. 2021;70(10):2971-2980. 01-12. Available from: https://www.fda.gov/drugs/
resources-information-approved-drugs/fda-approves-
doi: 10.1007/s00262-021-02852-4 pembrolizumab-chemoradiotherapy-figo-2014-stage-
42. Chang J, Quan S, Tian S, et al. Niraparib enhances antitumor iii-iva-cervical-cancer#:~:text=IVA%20cervical%20
immunity and contributes to the efficacy of PD-L1 blockade cancer-,FDA%20approves%20pembrolizumab%20
with%20chemoradiotherapy%20for%20FIGO%202014%20
in cervical cancer. J Cancer Res Clin Oncol. 2024;150(6):304.
Stage%20III,Stage%20III%2DIVA%20cervical%20cancer
doi: 10.1007/s00432-024-05819-x [Last accessed 2024 Dec 30].

Volume 9 Issue 2 (2025) 180 doi:10.36922/ejmo.8074